UA75091C2 - Tryptamine derivatives, similar compounds and pharmaceuticals containing them - Google Patents

Tryptamine derivatives, similar compounds and pharmaceuticals containing them Download PDF

Info

Publication number: UA75091C2
Authority: UA; Ukraine
Prior art keywords: diseases; alkyl; melatonin; disorders; aryl
Prior art date: 2000-10-03

Application number

UA2003043421A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Neurim Pharma 1991

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-03

Filing date

2001-09-25

Publication date

2006-03-15

2001-09-25 Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991

2006-03-15 Publication of UA75091C2 publication Critical patent/UA75091C2/uk

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 59
APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical class C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 title claims description 16
239000003814 drug Substances 0.000 title abstract description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 39
239000000203 mixture Substances 0.000 claims abstract description 23
208000035475 disorder Diseases 0.000 claims abstract description 13
210000003169 central nervous system Anatomy 0.000 claims abstract description 9
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
208000020016 psychiatric disease Diseases 0.000 claims abstract description 9
150000003839 salts Chemical class 0.000 claims abstract description 9
208000015114 central nervous system disease Diseases 0.000 claims abstract description 6
230000001613 neoplastic effect Effects 0.000 claims abstract description 6
201000010099 disease Diseases 0.000 claims description 26
238000011282 treatment Methods 0.000 claims description 19
230000033764 rhythmic process Effects 0.000 claims description 11
241001465754 Metazoa Species 0.000 claims description 10
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
239000002904 solvent Substances 0.000 claims description 9
230000032683 aging Effects 0.000 claims description 8
125000003118 aryl group Chemical group 0.000 claims description 8
125000001041 indolyl group Chemical group 0.000 claims description 7
206010019233 Headaches Diseases 0.000 claims description 6
208000019695 Migraine disease Diseases 0.000 claims description 6
231100000869 headache Toxicity 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
230000000737 periodic effect Effects 0.000 claims description 6
230000002265 prevention Effects 0.000 claims description 6
210000002307 prostate Anatomy 0.000 claims description 6
208000024172 Cardiovascular disease Diseases 0.000 claims description 5
239000002671 adjuvant Substances 0.000 claims description 5
208000030172 endocrine system disease Diseases 0.000 claims description 5
210000000987 immune system Anatomy 0.000 claims description 5
201000001881 impotence Diseases 0.000 claims description 5
230000001314 paroxysmal effect Effects 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 4
238000009395 breeding Methods 0.000 claims description 4
230000001488 breeding effect Effects 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
206010027599 migraine Diseases 0.000 claims description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
239000003755 preservative agent Substances 0.000 claims description 4
239000003995 emulsifying agent Substances 0.000 claims description 3
239000001257 hydrogen Substances 0.000 claims description 3
229940126601 medicinal product Drugs 0.000 claims description 3
238000000034 method Methods 0.000 claims description 3
229920006395 saturated elastomer Polymers 0.000 claims description 3
230000002292 Radical scavenging effect Effects 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
230000003078 antioxidant effect Effects 0.000 claims description 2
238000013270 controlled release Methods 0.000 claims description 2
239000002537 cosmetic Substances 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims description 2
230000002335 preservative effect Effects 0.000 claims description 2
208000017497 prostate disease Diseases 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims 2
125000000623 heterocyclic group Chemical group 0.000 claims 1
238000002347 injection Methods 0.000 claims 1
239000007924 injection Substances 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
230000001193 melatoninergic effect Effects 0.000 abstract description 7
230000007958 sleep Effects 0.000 abstract description 7
208000019116 sleep disease Diseases 0.000 abstract description 7
208000011580 syndromic disease Diseases 0.000 abstract description 5
208000001456 Jet Lag Syndrome Diseases 0.000 abstract description 4
208000019888 Circadian rhythm sleep disease Diseases 0.000 abstract description 3
206010010904 Convulsion Diseases 0.000 abstract description 3
208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 abstract description 3
230000004770 neurodegeneration Effects 0.000 abstract description 3
208000015122 neurodegenerative disease Diseases 0.000 abstract description 3
208000012672 seasonal affective disease Diseases 0.000 abstract description 3
230000003280 chronobiological effect Effects 0.000 abstract description 2
206010015037 epilepsy Diseases 0.000 abstract description 2
238000004519 manufacturing process Methods 0.000 abstract description 2
208000019901 Anxiety disease Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
230000003111 delayed effect Effects 0.000 abstract 1
230000009758 senescence Effects 0.000 abstract 1
229960003987 melatonin Drugs 0.000 description 77
DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 74
YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 72
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
239000000243 solution Substances 0.000 description 20
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
239000000047 product Substances 0.000 description 16
210000004027 cell Anatomy 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
230000000694 effects Effects 0.000 description 10
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
235000017557 sodium bicarbonate Nutrition 0.000 description 8
229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
229930195712 glutamate Natural products 0.000 description 7
102000001419 Melatonin receptor Human genes 0.000 description 6
108050009605 Melatonin receptor Proteins 0.000 description 6
241000700159 Rattus Species 0.000 description 6
210000004556 brain Anatomy 0.000 description 6
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
210000001700 mitochondrial membrane Anatomy 0.000 description 6
239000000126 substance Substances 0.000 description 6
JTEJPPKMYBDEMY-UHFFFAOYSA-N 5-methoxytryptamine Chemical compound COC1=CC=C2NC=C(CCN)C2=C1 JTEJPPKMYBDEMY-UHFFFAOYSA-N 0.000 description 4
241000699800 Cricetinae Species 0.000 description 4
241000282412 Homo Species 0.000 description 4
208000018737 Parkinson disease Diseases 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
238000009739 binding Methods 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 3
PYOUAIQXJALPKW-UHFFFAOYSA-N 2-(5-methyl-1H-indol-3-yl)ethanamine Chemical compound CC1=CC=C2NC=C(CCN)C2=C1 PYOUAIQXJALPKW-UHFFFAOYSA-N 0.000 description 3
RAGRTYREMCPEIV-UHFFFAOYSA-N 5-fluoro-2,4-dinitroaniline Chemical compound NC1=CC(F)=C([N+]([O-])=O)C=C1[N+]([O-])=O RAGRTYREMCPEIV-UHFFFAOYSA-N 0.000 description 3
229940097276 5-methoxytryptamine Drugs 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 3
206010062767 Hypophysitis Diseases 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
230000027455 binding Effects 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000007423 decrease Effects 0.000 description 3
229960003638 dopamine Drugs 0.000 description 3
230000035558 fertility Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
LZBXUWOTXPNTNQ-UHFFFAOYSA-N n-(5-fluoro-2,4-dinitrophenyl)acetamide Chemical compound CC(=O)NC1=CC(F)=C([N+]([O-])=O)C=C1[N+]([O-])=O LZBXUWOTXPNTNQ-UHFFFAOYSA-N 0.000 description 3
210000001577 neostriatum Anatomy 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
210000004560 pineal gland Anatomy 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
208000022925 sleep disturbance Diseases 0.000 description 3
239000007858 starting material Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
208000017701 Endocrine disease Diseases 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
102000016267 Leptin Human genes 0.000 description 2
108010092277 Leptin Proteins 0.000 description 2
FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 2
241001494479 Pecora Species 0.000 description 2
206010036618 Premenstrual syndrome Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
208000034972 Sudden Infant Death Diseases 0.000 description 2
206010042440 Sudden infant death syndrome Diseases 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
235000013305 food Nutrition 0.000 description 2
210000002149 gonad Anatomy 0.000 description 2
230000012010 growth Effects 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
210000001320 hippocampus Anatomy 0.000 description 2
235000012907 honey Nutrition 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
208000031424 hyperprolactinemia Diseases 0.000 description 2
230000000147 hypnotic effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
229940039781 leptin Drugs 0.000 description 2
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
210000003635 pituitary gland Anatomy 0.000 description 2
230000002028 premature Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
230000001932 seasonal effect Effects 0.000 description 2
230000008454 sleep-wake cycle Effects 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
210000003523 substantia nigra Anatomy 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
QLWKTGDEPLRFAT-UHFFFAOYSA-N 5-Methoxytryptophol Chemical compound COC1=CC=C2NC=C(CCO)C2=C1 QLWKTGDEPLRFAT-UHFFFAOYSA-N 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
206010001540 Akathisia Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
208000022497 Cocaine-Related disease Diseases 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
206010056438 Growth hormone deficiency Diseases 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010021033 Hypomenorrhoea Diseases 0.000 description 1
241000899793 Hypsophrys nicaraguensis Species 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
244000062730 Melissa officinalis Species 0.000 description 1
235000010654 Melissa officinalis Nutrition 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000027089 Parkinsonian disease Diseases 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
206010062519 Poor quality sleep Diseases 0.000 description 1
206010071019 Prostatic dysplasia Diseases 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
206010043118 Tardive Dyskinesia Diseases 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960001413 acetanilide Drugs 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
239000003098 androgen Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000003712 anti-aging effect Effects 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000002180 anti-stress Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000002060 circadian Effects 0.000 description 1
201000006145 ***e dependence Diseases 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
230000001463 effect on reproduction Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000007368 endocrine function Effects 0.000 description 1
210000003372 endocrine gland Anatomy 0.000 description 1
201000010063 epididymitis Diseases 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
102000015694 estrogen receptors Human genes 0.000 description 1
108010038795 estrogen receptors Proteins 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000005281 excited state Effects 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000002871 fertility agent Substances 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
230000006266 hibernation Effects 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000004410 intraocular pressure Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000000865 liniment Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
239000006210 lotion Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000035800 maturation Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000028161 membrane depolarization Effects 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000007230 neural mechanism Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
230000000422 nocturnal effect Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000000247 oncostatic effect Effects 0.000 description 1
-1 or CE 3 Chemical group 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
208000023958 prostate neoplasm Diseases 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
210000001625 seminal vesicle Anatomy 0.000 description 1
201000002859 sleep apnea Diseases 0.000 description 1
230000003860 sleep quality Effects 0.000 description 1
230000037321 sleepiness Effects 0.000 description 1
230000002557 soporific effect Effects 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
241000894007 species Species 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
239000002438 stress hormone Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
230000036325 urinary excretion Effects 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
201000010653 vesiculitis Diseases 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Obesity (AREA)
Psychology (AREA)
Psychiatry (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Emergency Medicine (AREA)
Toxicology (AREA)
Ophthalmology & Optometry (AREA)
Biochemistry (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UA2003043421A 2000-10-03 2001-09-25 Tryptamine derivatives, similar compounds and pharmaceuticals containing them UA75091C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL138825A IL138825A (en)	2000-10-03	2000-10-03	Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds
PCT/IL2001/000898 WO2002028347A2 (en)	2000-10-03	2001-09-25	Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them

Publications (1)

Publication Number	Publication Date
UA75091C2 true UA75091C2 (en)	2006-03-15

Family

ID=11074694

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2003043421A UA75091C2 (en)	2000-10-03	2001-09-25	Tryptamine derivatives, similar compounds and pharmaceuticals containing them

Country Status (40)

Country	Link
US (2)	US6780884B2 (zh)
EP (1)	EP1331935B1 (zh)
JP (1)	JP2004533986A (zh)
KR (1)	KR100855385B1 (zh)
CN (1)	CN100518735C (zh)
AR (1)	AR035587A1 (zh)
AT (1)	ATE409474T1 (zh)
AU (1)	AU9416201A (zh)
BG (1)	BG107759A (zh)
BR (1)	BR0114464A (zh)
CA (1)	CA2423628C (zh)
CL (1)	CL2001002303A1 (zh)
CR (1)	CR6968A (zh)
CY (1)	CY1110417T1 (zh)
CZ (1)	CZ301098B6 (zh)
DE (1)	DE60136003D1 (zh)
DK (1)	DK1331935T3 (zh)
EA (1)	EA005918B1 (zh)
EE (1)	EE05192B1 (zh)
ES (1)	ES2315307T3 (zh)
GT (1)	GT200100197A (zh)
HK (1)	HK1074163A1 (zh)
HN (1)	HN2001000218A (zh)
HU (1)	HU227163B1 (zh)
IL (1)	IL138825A (zh)
IS (1)	IS2607B (zh)
MX (1)	MXPA03002612A (zh)
NO (1)	NO20031396L (zh)
NZ (1)	NZ525587A (zh)
PA (1)	PA8529801A1 (zh)
PE (1)	PE20020411A1 (zh)
PL (1)	PL365679A1 (zh)
PT (1)	PT1331935E (zh)
SI (1)	SI1331935T1 (zh)
SK (1)	SK4042003A3 (zh)
TW (1)	TWI270544B (zh)
UA (1)	UA75091C2 (zh)
UY (1)	UY26946A1 (zh)
WO (1)	WO2002028347A2 (zh)
ZA (1)	ZA200303113B (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005060711A2 (en) *	2003-12-19	2005-07-07	Elixir Pharmaceuticals, Inc.	Methods of treating a disorder
CA2556753C (en) *	2004-02-20	2014-11-25	Lifescape Biosciences Incorporated	Compositions and methods for sleep regulation
CN101233121A (zh) *	2005-06-10	2008-07-30	彼帕科学公司	Parp调节剂和癌症的治疗
US7622495B2 (en)	2006-10-03	2009-11-24	Neurim Pharmaceuticals (1991) Ltd.	Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
AU2008271911B2 (en)	2007-06-29	2014-08-07	Phovitreal Pty Ltd	Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration
CA2723816C (en) *	2008-05-13	2017-06-20	Yale University	Chimeric small molecules for the recruitment of antibodies to cancer cells
US8852630B2 (en)	2008-05-13	2014-10-07	Yale University	Chimeric small molecules for the recruitment of antibodies to cancer cells
KR20220083846A (ko)	2011-05-31	2022-06-20	클라렌슈 피티와이 리미티드	광선 요법 장치
WO2013063492A1 (en) *	2011-10-28	2013-05-02	Board Of Regents, The University Of Texas System	Novel compositions and methods for treating cancer
CN102816103B (zh) *	2012-08-20	2014-05-07	冉瑞琼	硫化天冬氨酸修饰的退黑素衍生物及其应用
SG11201807079UA (en) *	2016-03-14	2018-09-27	Somalogic Inc	Compounds and methods for the synthesis of 5-(n-protected-tryptaminocarboxyamide)-2'-deoxyuridine phosphoramidate for incorporation into a nucleic sequence

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL79264A0 (en) *	1986-06-27	1986-09-30	Univ Ramot	Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US6310085B1 (en) *	1997-10-03	2001-10-30	Clarencew Pty Ltd.	Method for the treatment of neurological or neuropsychiatric disorders
AUPO274596A0 (en) *	1996-10-04	1996-10-31	Armstrong, Stuart Maxwell	Method for the treatment of neurological or neuropsychiatric disorders

2000
- 2000-10-03 IL IL138825A patent/IL138825A/en not_active IP Right Cessation
2001
- 2001-09-14 TW TW090122940A patent/TWI270544B/zh not_active IP Right Cessation
- 2001-09-25 CA CA2423628A patent/CA2423628C/en not_active Expired - Fee Related
- 2001-09-25 KR KR1020037004661A patent/KR100855385B1/ko not_active IP Right Cessation
- 2001-09-25 CL CL2001002303A patent/CL2001002303A1/es unknown
- 2001-09-25 UY UY26946A patent/UY26946A1/es not_active Application Discontinuation
- 2001-09-25 CN CNB018168043A patent/CN100518735C/zh not_active Expired - Fee Related
- 2001-09-25 US US10/381,976 patent/US6780884B2/en not_active Expired - Fee Related
- 2001-09-25 AR ARP010104520A patent/AR035587A1/es unknown
- 2001-09-25 CZ CZ20030940A patent/CZ301098B6/cs not_active IP Right Cessation
- 2001-09-25 UA UA2003043421A patent/UA75091C2/uk unknown
- 2001-09-25 MX MXPA03002612A patent/MXPA03002612A/es active IP Right Grant
- 2001-09-25 BR BR0114464-2A patent/BR0114464A/pt not_active Application Discontinuation
- 2001-09-25 ES ES01974651T patent/ES2315307T3/es not_active Expired - Lifetime
- 2001-09-25 EP EP01974651A patent/EP1331935B1/en not_active Expired - Lifetime
- 2001-09-25 DE DE60136003T patent/DE60136003D1/de not_active Expired - Lifetime
- 2001-09-25 EA EA200300436A patent/EA005918B1/ru not_active IP Right Cessation
- 2001-09-25 JP JP2002531973A patent/JP2004533986A/ja active Pending
- 2001-09-25 SK SK404-2003A patent/SK4042003A3/sk unknown
- 2001-09-25 EE EEP200300135A patent/EE05192B1/xx not_active IP Right Cessation
- 2001-09-25 AT AT01974651T patent/ATE409474T1/de active
- 2001-09-25 NZ NZ525587A patent/NZ525587A/en unknown
- 2001-09-25 WO PCT/IL2001/000898 patent/WO2002028347A2/en active IP Right Grant
- 2001-09-25 DK DK01974651T patent/DK1331935T3/da active
- 2001-09-25 PL PL01365679A patent/PL365679A1/xx not_active Application Discontinuation
- 2001-09-25 AU AU9416201A patent/AU9416201A/xx not_active Withdrawn
- 2001-09-25 SI SI200130889T patent/SI1331935T1/sl unknown
- 2001-09-25 HU HU0302616A patent/HU227163B1/hu not_active IP Right Cessation
- 2001-09-25 PT PT01974651T patent/PT1331935E/pt unknown
- 2001-09-26 PE PE2001000960A patent/PE20020411A1/es not_active Application Discontinuation
- 2001-09-27 GT GT200100197A patent/GT200100197A/es unknown
- 2001-10-01 PA PA20018529801A patent/PA8529801A1/es unknown
- 2001-10-02 HN HN2001000218A patent/HN2001000218A/es unknown
2003
- 2003-03-21 IS IS6752A patent/IS2607B/is unknown
- 2003-03-27 NO NO20031396A patent/NO20031396L/no not_active Application Discontinuation
- 2003-04-23 ZA ZA200303113A patent/ZA200303113B/xx unknown
- 2003-04-24 BG BG107759A patent/BG107759A/bg unknown
- 2003-05-02 CR CR6968A patent/CR6968A/es unknown
2004
- 2004-08-20 US US10/921,823 patent/US20050020664A1/en not_active Abandoned
2005
- 2005-06-24 HK HK05105286.7A patent/HK1074163A1/xx not_active IP Right Cessation
2008
- 2008-12-22 CY CY20081101480T patent/CY1110417T1/el unknown

Also Published As

Publication number	Publication date
CN100518735C (zh)	2009-07-29
EE200300135A (et)	2003-08-15
EP1331935A4 (en)	2004-12-01
BG107759A (bg)	2004-01-30
IS2607B (is)	2010-04-15
AU9416201A (en)	2002-04-15
AR035587A1 (es)	2004-06-16
KR100855385B1 (ko)	2008-09-04
CN1582147A (zh)	2005-02-16
CZ2003940A3 (cs)	2003-10-15
GT200100197A (es)	2002-05-08
SK4042003A3 (en)	2003-09-11
EA200300436A1 (ru)	2003-10-30
KR20030051689A (ko)	2003-06-25
TWI270544B (en)	2007-01-11
PA8529801A1 (es)	2002-12-30
JP2004533986A (ja)	2004-11-11
EA005918B1 (ru)	2005-06-30
EP1331935B1 (en)	2008-10-01
US6780884B2 (en)	2004-08-24
BR0114464A (pt)	2004-01-20
CL2001002303A1 (es)	2010-06-25
EP1331935A2 (en)	2003-08-06
ES2315307T3 (es)	2009-04-01
ZA200303113B (en)	2004-07-23
CY1110417T1 (el)	2015-04-29
ATE409474T1 (de)	2008-10-15
PL365679A1 (en)	2005-01-10
IS6752A (is)	2003-03-21
US20040029950A1 (en)	2004-02-12
HU227163B1 (en)	2010-09-28
DE60136003D1 (de)	2008-11-13
CA2423628A1 (en)	2002-04-11
PE20020411A1 (es)	2002-05-16
HUP0302616A2 (hu)	2003-11-28
SI1331935T1 (sl)	2009-04-30
NO20031396D0 (no)	2003-03-27
HK1074163A1 (en)	2005-11-04
IL138825A (en)	2006-06-11
WO2002028347A3 (en)	2002-07-04
EE05192B1 (et)	2009-08-17
HN2001000218A (es)	2002-05-09
MXPA03002612A (es)	2004-04-02
US20050020664A1 (en)	2005-01-27
IL138825A0 (en)	2001-10-31
UY26946A1 (es)	2001-11-30
CZ301098B6 (cs)	2009-11-04
CR6968A (es)	2004-02-25
DK1331935T3 (da)	2009-02-02
NZ525587A (en)	2005-03-24
PT1331935E (pt)	2009-01-19
NO20031396L (no)	2003-03-27
CA2423628C (en)	2011-04-26
WO2002028347A2 (en)	2002-04-11

Publication	Publication Date	Title
US6140372A (en)	2000-10-31	Acyl derivatives of melatonin and of melatoninergic analogues and their use as medicinal products
US7355054B2 (en)	2008-04-08	Indole derivatives
BR112013000783A2 (pt)	2020-11-03	derivados arilamídicos tendo propriedades antiandrogênicas
UA75091C2 (en)	2006-03-15	Tryptamine derivatives, similar compounds and pharmaceuticals containing them
JPH08325217A (ja)	1996-12-10	新規なアルコキシアリール化合物、その製造方法及びそれらを含む医薬組成物
US6090854A (en)	2000-07-18	Aryloxyanilides and related compounds
JP3513876B2 (ja)	2004-03-31	メラトニン作用性類似物としてのインドール誘導体
AU2001294162B2 (en)	2007-09-27	Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
JP5641054B2 (ja)	2014-12-17	新規化合物、並びに、キネシンスピンドルタンパク質阻害剤及びその応用
AU2001294162A2 (en)	2003-07-24	Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
AU2001294162A1 (en)	2002-06-27	Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
PT2298766E (pt)	2013-11-07	Formulação farmacêutica compreendendo derivados de piridina substituída